H. Lundbeck A/S (Lundbeck) today commenced its launch of Selincro® in Denmark, making the product available to alcohol-dependent patients in Denmark with a high drinking risk level. It is estimated that 585,000 Danes have a harmful alcohol intake, of whom about 140,000 are alcohol-dependent.. Selincro® is the first and only medicine approved for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification.
Further reading
Leave a Reply
You must be logged in to post a comment.